Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry
暂无分享，去创建一个
V. Arrazubi | P. Jiménez-Fonseca | J. Gallego | L. Visa | J. Cano | A. Carmona-Bayonas | A. Custodio | M. Gil | R. Hernández | I. Macías | M. Limón | P. Pimentel | P. Cerda | M. M. Richard | N. M. Lago | A. F. Montes | A. Calvo | M. Diez | E. M. de Castro | R. V. Tocino | M. Granja | A. Carnicero | L. G. González | M. Rambla | M. Mangas | Sena Valcarcel | Lola Macia-Rivas | Carolina Hernández Pérez | Francisco García Navalón